Feb 4 (Reuters) - Pfizer Inc PFE.N:
PFIZER: EXPECT HIGHER GROSS-TO-NET IMPACT ON OUR REVENUES FOR ALL DRUGS IN THE BEGINNING OF 2025 WHEN COMPARED TO 2024 - PREPARED REMARKS
PFIZER: EXPECT HIGHER GROSS-TO-NET IMPACT ON REVENUES FOR ALL DRUGS TO MODERATE THROUGH REMAINDER OF 2025, WHEN COMPARED TO 2024
PFIZER SAYS BELIEVE OUR REVENUE VOLATILITY IS LARGELY IN THE PAST AS COVID- RELATED UNCERTAINTIES HAVE DIMINISHED
PFIZER: CONTINUE TO SEE STABILIZING PATTERNS IN DISEASE BURDEN WITH STRONG CORRELATION BETWEEN COVID-19 BURDEN OF DISEASE AND PAXLOVID UTILIZATION
PFIZER SEES THE SAME STABILIZING PATTERNS IN U.S. VACCINATION RATES AT RELATIVELY LOW LEVELS
PFIZER: CONFIDENT THAT OUR COVID-19 PORTFOLIO WILL CONTINUE TO BE A PREDICTABLE AND DURABLE CONTRIBUTOR TO OUR BUSINESS
PFIZER: INTEND TO MONETIZE OUR REMAINING HALEON INVESTMENT IN A "PRUDENT FASHION" DURING 2025
PFIZER: CONTINUE TO EVALUATE OTHER STRATEGIES TO IMPROVE OUR NETWORK STRUCTURE AND PRODUCT PORTFOLIO
PFIZER: ACHIEVED MARKET LEADERSHIP POSITION FOR SEASON IN SHIPPED DOSES FOR ABRYSVO, WITH ABOUT 13 PERCENTAGE POINT INCREASE IN MARKET SHARE
Source text: [ID:]
Further company coverage: PFE.N